← Study Library
Review · 2012
Preclinicalcounts toward this tierThe regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients
Treadwell T, Kleinman HK, Crockford D, Hardy MA, Guarnera GT, Goldstein AL · Annals of the New York Academy of Sciences
Preclinicalcounts toward this tier
Summarises consistent acceleration of healing across rodent models and states that in the stasis and pressure ulcer trials Tβ4 "accelerate[d] healing by almost a month in those patients that did heal" — a conditional, within-healers claim rather than a difference in how many patients healed.
- Population
- Review of Tβ4 dermal-repair studies and the two phase 2 ulcer trials
- Intervention
- n/a
- Comparator
- n/a
- Limitations
- Authored by the sponsor's team and trial investigators; the registry results for both cited trials show equal healing proportions between arms.
Cited by
1 entry references this study
- TB-500 / thymosin beta-4PRECL.
Peptides → Preclinical & experimental